A retrospective study assessing efficacy of Rituxan® in patients with Immune thrombocytopenia

Trial Profile

A retrospective study assessing efficacy of Rituxan® in patients with Immune thrombocytopenia

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jan 2017 New trial record
    • 06 Dec 2016 Results (n=233) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top